BridgeMD
New treatment option for Melanoma Advanced
Official title RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
ClinicalTrials.gov ID: NCT07445022
What this study is testing
What is tunlametinib?
tunlametinib is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for melanoma advanced.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged ≥18 years (inclusive), male or female;
- Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
- Prior genetic testing results showing positive NRAS mutation;
- Patients who have failed prior anti-PD-1/PD-L1 therapy;
- Able to take oral medications;
You likely can't join if
- Currently participating in other clinical trials of drugs;
- Patients who are pregnant or breastfeeding;
- Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;
- Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the...
See the full eligibility criteria
- Aged ≥18 years (inclusive), male or female;
- Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
- Prior genetic testing results showing positive NRAS mutation;
- Patients who have failed prior anti-PD-1/PD-L1 therapy;
- Able to take oral medications;
- Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.
- Currently participating in other clinical trials of drugs;
- Patients who are pregnant or breastfeeding;
- Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;
- Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.